SCHEMBL375910

SCHEMBL375910

Nc1ncnc2c1ncn2[C@H]1C[C@H](OP(=O)(O)O)[C@@H](COP(=O)(O)O)O1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY1 P47900 2/20 0.64
DNPH1 O43598 1/20 0.64
PRKAB2 O43741 1/20 0.64
TRPM2 O94759 1/20 0.64
LDHA P00338 1/20 0.64
ADRB2 P07550 1/20 0.64
FBP1 P09467 1/20 0.64
SRC P12931 1/20 0.64
ADORA1 P30542 1/20 0.64
P2RY2 P41231 1/20 0.64
PRKAG1 P54619 1/20 0.64
PRKAA2 P54646 1/20 0.64
PDE4D Q08499 1/20 0.64
KCNH2 Q12809 1/20 0.64
PRKAA1 Q13131 1/20 0.64
PDE3A Q14432 1/20 0.64
SMN1; SMN2 Q16637 1/20 0.64
TAS1R3 Q7RTX0 1/20 0.64
TAS1R1 Q7RTX1 1/20 0.64
P2RY11 Q96G91 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24059946 1.00 P2RY1 (0.64) P2RY1DNPH1PRKAB2TRPM2LDHA
SCHEMBL20266309 1.00 P2RY1 (0.64) P2RY1DNPH1PRKAB2TRPM2LDHA
SCHEMBL20282730 1.00 P2RY1 (0.64) P2RY1DNPH1PRKAB2TRPM2LDHA
SCHEMBL16691022 0.93 POLB (0.61) P2RY1DNPH1PRKAB2TRPM2LDHA
SCHEMBL20428118 0.91 P2RY1 (0.63) P2RY1DNPH1PRKAB2TRPM2LDHA
SCHEMBL18107894 0.91 POLB (0.58) P2RY1DNPH1PRKAB2TRPM2LDHA
SCHEMBL1969290 0.91 POLB (0.59) P2RY1DNPH1PRKAB2TRPM2LDHA
SCHEMBL1969284 0.91 POLB (0.59) P2RY1DNPH1PRKAB2TRPM2LDHA
SCHEMBL20016487 0.91 POLB (0.59) P2RY1DNPH1PRKAB2TRPM2LDHA
SCHEMBL25766886 0.90 P2RY1 (0.62) P2RY1DNPH1PRKAB2TRPM2LDHA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024239431-A1 METHOD FOR PHOSPHORYLATION OF NUCLEIC ACID AT 3' END AND LIBRARY CONSTRUCTION 深圳华大智造科技股份有限公司 2024-11-28 WO claimed
CN-117137048-A Flavor composition, food comprising the same, and method for increasing the flavor intensity of the umami taste of food 马斯公司 2023-12-01 CN claimed
EP-3829565-A1 INORGANIC-ORGANIC HYBRID COMPOUNDS INCLUDING ORGANIC PLATINUM-CONTAINING ANIONS, FOR USE IN MEDICINE Karlsruher Institut für Technologie (DE) 2021-06-09 EP claimed
WO-2020025488-A1 INORGANIC-ORGANIC HYBRID COMPOUNDS INCLUDING ORGANIC PLATINUM-CONTAINING ANIONS, FOR USE IN MEDICINE Karlsruher Institut für Technologie (DE) 2020-02-06 WO claimed
EP-3122756-A1 INORGANIC-ORGANIC HYBRID COMPOUND Karlsruher Institut für Technologie (DE) 2017-02-01 EP claimed
WO-2015144282-A1 INORGANIC-ORGANIC HYBRID COMPOUND Karlsruher Institut für Technologie (DE) 2015-10-01 WO claimed
EP-1624753-B1 PURINERGIC MODULATION OF SMELL UNIV UTAH RES FOUND (US) 2012-01-25 EP claimed
EP-1595120-B1 METAL COATED NANOCRYSTALLINE SILICON AS AN ACTIVE SURFACE ENHANCED RAMAN SPECTROSCOPY (SERS) SUBSTRATE INTEL CORP (US) 2009-12-30 EP claimed
EP-0929218-A4 P2Y RECEPTOR ANTAGONISTS UNIV NORTH CAROLINA (US) 2001-05-16 EP claimed
EP-0929218-A2 P2Y RECEPTOR ANTAGONISTS UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 1999-07-21 EP claimed
WO-1998018430-A2 P2Y RECEPTOR ANTAGONISTS THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 1998-05-07 WO claimed
EP-0458971-B1 INOSINE GUANOSINE KINASE KYOWA HAKKO KOGYO KK (JP) 1996-01-03 EP claimed
US-20260060965-A1 MODULATING THE ACUTE FOREIGN BODY REACTION TO REDUCE STENOSIS RES INSTITUTE AT NATIONWIDE CHILDREN’S HOSPITAL (US) 2026-03-05 US disclosed
WO-2024239431-A1 METHOD FOR PHOSPHORYLATION OF NUCLEIC ACID AT 3' END AND LIBRARY CONSTRUCTION 深圳华大智造科技股份有限公司 2024-11-28 WO disclosed
EP-4403042-A2 FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME Mars, Incorporated (US) 2024-07-24 EP disclosed
EP-3229612-B1 USE OF FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME MARS INC (US) 2024-06-26 EP disclosed
WO-2001051490-A1 METHANOCARBA CYCLOALKYL NUCLEOSIDE ANALOGUES THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2001-07-19 WO disclosed
EP-0929218-A4 P2Y RECEPTOR ANTAGONISTS UNIV NORTH CAROLINA (US) 2001-05-16 EP disclosed
EP-0929218-A2 P2Y RECEPTOR ANTAGONISTS UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 1999-07-21 EP disclosed
WO-1998018430-A2 P2Y RECEPTOR ANTAGONISTS THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 1998-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260060965-A1 MODULATING THE ACUTE FOREIGN BODY REACTION TO REDUCE STENOSIS AGTR1, P2RY12, AGTR2 P2RY1 7/4885DNPH1 2639/4885PRKAB2 2533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.